465 related articles for article (PubMed ID: 16741927)
21. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B.
Frank R; Zhang J; Uchida H; Meyers S; Hiebert SW; Nimer SD
Oncogene; 1995 Dec; 11(12):2667-74. PubMed ID: 8545124
[TBL] [Abstract][Full Text] [Related]
22. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.
Jin W; Wu K; Li YZ; Yang WT; Zou B; Zhang F; Zhang J; Wang KK
Oncogene; 2013 Apr; 32(15):1978-87. PubMed ID: 22641217
[TBL] [Abstract][Full Text] [Related]
23. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.
Wang YY; Zhou GB; Yin T; Chen B; Shi JY; Liang WX; Jin XL; You JH; Yang G; Shen ZX; Chen J; Xiong SM; Chen GQ; Xu F; Liu YW; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1104-9. PubMed ID: 15650049
[TBL] [Abstract][Full Text] [Related]
24. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES
Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743
[TBL] [Abstract][Full Text] [Related]
25. Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2.
Kohzaki H; Ito K; Huang G; Wee HJ; Murakami Y; Ito Y
Oncogene; 1999 Jul; 18(28):4055-62. PubMed ID: 10435586
[TBL] [Abstract][Full Text] [Related]
26. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
27. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
28. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO.
Kuchenbauer F; Schnittger S; Look T; Gilliland G; Tenen D; Haferlach T; Hiddemann W; Buske C; Schoch C
Br J Haematol; 2006 Sep; 134(6):616-9. PubMed ID: 16938118
[TBL] [Abstract][Full Text] [Related]
29. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.
Tabe Y; Jin L; Contractor R; Gold D; Ruvolo P; Radke S; Xu Y; Tsutusmi-Ishii Y; Miyake K; Miyake N; Kondo S; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M
Cell Death Differ; 2007 Aug; 14(8):1443-56. PubMed ID: 17464329
[TBL] [Abstract][Full Text] [Related]
30. Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells.
Trombly DJ; Whitfield TW; Padmanabhan S; Gordon JA; Lian JB; van Wijnen AJ; Zaidi SK; Stein JL; Stein GS
BMC Genomics; 2015 Apr; 16(1):309. PubMed ID: 25928846
[TBL] [Abstract][Full Text] [Related]
31. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.
Dunne J; Gascoyne DM; Lister TA; Brady HJ; Heidenreich O; Young BD
Cancer Res; 2010 May; 70(10):3985-95. PubMed ID: 20460523
[TBL] [Abstract][Full Text] [Related]
32. Transformation properties of the ETO gene, fusion partner in t(8:21) leukemias.
Wang J; Wang M; Liu JM
Cancer Res; 1997 Jul; 57(14):2951-5. PubMed ID: 9230207
[TBL] [Abstract][Full Text] [Related]
33. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.
Gessner A; Thomas M; Castro PG; Büchler L; Scholz A; Brümmendorf TH; Soria NM; Vormoor J; Greil J; Heidenreich O
Leukemia; 2010 Oct; 24(10):1751-9. PubMed ID: 20686504
[TBL] [Abstract][Full Text] [Related]
34. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.
Licht JD
Oncogene; 2001 Sep; 20(40):5660-79. PubMed ID: 11607817
[No Abstract] [Full Text] [Related]
35. Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia.
Huang S; Jiang MM; Chen GF; Qian K; Gao HH; Guan W; Shi JL; Liu AQ; Liu J; Wang BH; Li YH; Yu L
Chin Med J (Engl); 2016 Jun; 129(11):1355-62. PubMed ID: 27231175
[TBL] [Abstract][Full Text] [Related]
36. Detection and subcellular localization of an AML1 chimeric protein in the t(8;21) positive acute myeloid leukemia.
Sacchi N; Schiaffonati L; Magnani I; Pappalardo C; Hughes AJ; Darfler M; Hoogeveen AT
Oncogene; 1996 Jan; 12(2):437-44. PubMed ID: 8570222
[TBL] [Abstract][Full Text] [Related]
37. Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically.
Zapotocky M; Mejstrikova E; Smetana K; Stary J; Trka J; Starkova J
Cancer Lett; 2012 Jun; 319(2):144-153. PubMed ID: 22261333
[TBL] [Abstract][Full Text] [Related]
38. ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO.
Lausen J; Liu S; Fliegauf M; Lübbert M; Werner MH
Oncogene; 2006 Mar; 25(9):1349-57. PubMed ID: 16247445
[TBL] [Abstract][Full Text] [Related]
39. Detection of the AML1/ETO fusion transcript in the t(8;21) masked translocation in acute myelogenous leukemia.
Maruyama F; Yang P; Stass SA; Cork A; Freireich EJ; Lee MS; Chang KS
Cancer Res; 1993 Oct; 53(19):4449-51. PubMed ID: 8402610
[TBL] [Abstract][Full Text] [Related]
40. The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.
Bakshi R; Zaidi SK; Pande S; Hassan MQ; Young DW; Montecino M; Lian JB; van Wijnen AJ; Stein JL; Stein GS
J Cell Sci; 2008 Dec; 121(Pt 23):3981-90. PubMed ID: 19001502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]